FDA Approves First-in-Class Non-Opioid Pain Reliever
Journavx (suzetrigine) – a first-in-class, non-opioid analgesicA new non-opioid pain treatment option
On January 30, 2025, the FDA granted priority review for Journavx (suzetrigine) – a first-in-class, non-opioid analgesic for treating moderate to severe acute pain in adults.
How It Works
Journavx targets sodium channels in the peripheral nervous system, interrupting pain signals before they reach the brain — offering a novel mechanism of action with no opioid involvement.
Key Trial Results
- Evaluated in two surgical pain studies (abdominoplasty and bunionectomy).
- Patients using Journavx had significantly better pain relief than those on placebo.
- Common side effects: itching, muscle spasms, rash, and elevated creatine phosphokinase.
Warnings
Users should avoid grapefruit and strong CYP3A inhibitors due to interaction risk.
Why It Matters
This marks the first approval in a new class of non-opioid pain medicines, aligning with the FDA’s push to expand safer alternatives amid the opioid crisis.
Approved by: Vertex Pharmaceuticals
Designations: Breakthrough Therapy, Fast Track, Priority Review
Journavx offers a promising new option for acute pain relief — without the risks of opioids.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
Testosterone Regulation Takes a Sharp Turn
Why FDA’s December Panel Raises Red Flags Regulatory Analysis The FDA’s regulation of testosterone therapy has long been a model of cautious, evidence-based policymaking. For more than a decade, the agency maintained a consistent position: testosterone was approved...
How U.S. Testosterone Regulation Reached a Crossroads
How U.S. Testosterone Regulation Reached a Crossroads The FDA’s approach to testosterone therapy has undergone one of the most unusual and dramatic evolutions in modern drug regulation. What began as a cautious, evidence-driven posture in 2014 has, by late 2025,...
Has Industry Self-Regulation Been Effective?
Has Industry Self-Regulation Been Effective? Supplement industry self-regulation has helped in limited ways, but it has not been sufficient to ensure reliable safety. What has worked Voluntary GMP certifications (e.g., NSF, USP, Informed Choice) A minority of...